Evidence map›Paper›PMID 36201618›Full record

ArticleDiabetes2023

Recognition of mRNA Splice Variant and Secretory Granule Epitopes by CD4+ T Cells in Type 1 Diabetes.

Perrin Guyer, David Arribas-Layton, Anthony Manganaro, Cate Speake, Sandra Lord, Decio L Eizirik, Sally C Kent, Roberto Mallone, Eddie A James

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Perrin GuyerCenter for Translational Immunology, Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA.
David Arribas-LaytonCenter for Translational Immunology, Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA.
Anthony ManganaroDivision of Diabetes, Diabetes Center of Excellence, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA.
Cate SpeakeDiabetes Clinical Research Program and Center for Interventional Immunology, Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA.
Sandra LordDiabetes Clinical Research Program and Center for Interventional Immunology, Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA.
Decio L EizirikULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.
Sally C KentDivision of Diabetes, Diabetes Center of Excellence, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA.
Roberto MalloneINSERM, CNRS, Institut Cochin, Université de Paris, Paris, France.ORCID 0000-0002-9846-8861
Eddie A JamesCenter for Translational Immunology, Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA.ORCID 0000-0002-7217-5729
Virginia Mason Medical Center · USUniversity of Massachusetts Chan Medical School · USCentre National de la Recherche Scientifique · FRUniversité Libre de Bruxelles · BE

Funding

Human Islet-Infiltrating T Cell Biology: Reactivity, Structure, and FunctionUC4DK116284 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HARLAN, DAVID MARSHALL, KENT, SALLY CHOATE · 2017 to 2017
$2.0M
NIDDK NIH HHS UC4 DK116284
6 · The paper itself

Abstract

A recent discovery effort resulted in identification of novel splice variant and secretory granule antigens within the HLA class I peptidome of human islets and documentation of their recognition by CD8+ T cells from peripheral blood and human islets. In the current study, we applied a systematic discovery process to identify novel CD4+ T cell epitopes derived from these candidate antigens. We predicted 145 potential epitopes spanning unique splice junctions and within conventional secretory granule antigens and measured their in vitro binding to DRB1*04:01. We generated HLA class II tetramers for the 35 peptides with detectable binding and used these to assess immunogenicity and isolate T cell clones. Tetramers corresponding to peptides with verified immunogenicity were then used to label T cells specific for these putative epitopes in peripheral blood. T cells that recognize distinct epitopes derived from a cyclin I splice variant, neuroendocrine convertase 2, and urocortin-3 were detected at frequencies that were similar to those of an immunodominant proinsulin epitope. Cells specific for these novel epitopes predominantly exhibited a Th1-like surface phenotype. Among the three epitopes, responses to the cyclin I peptide exhibited a distinct memory profile. Responses to neuroendocrine convertase 2 were detected among pancreatic infiltrating T cells. These results further establish the contribution of unconventional antigens to the loss of tolerance in autoimmune diabetes.

Indexed as

CD4-Positive T-LymphocytesDiabetes Mellitus, Type 1Alternative SplicingCyclin IEpitopes, T-LymphocyteHumansPeptidesSecretory VesiclesCyclin IEpitopes, T-LymphocytePeptides

Identifiers

PMID36201618
PMCPMC9797322
OpenAlexW4302425104

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.